α₁-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans.

Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME
J Clin Psychopharmacol. 2013 33 (5): 658-66

PMID: 23857311 · DOI:10.1097/JCP.0b013e3182979d32

Preclinical studies implicate a role for α₁-noradrenergic receptors in the effects of psychostimulants, including 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The present study evaluated the effects of the α₁-noradrenergic receptor antagonist doxazosin on the acute pharmacodynamic and pharmacokinetic response to MDMA in 16 healthy subjects. Doxazosin (8 mg/d) or placebo was administered for 3 days before MDMA (125 mg) or placebo using a randomized, double-blind, placebo-controlled, 4-session, crossover design. Doxazosin reduced MDMA-induced elevations in blood pressure, body temperature, and moderately attenuated positive mood but enhanced tachycardia associated with MDMA. The results indicate that α₁-adrenergic receptors contribute to the acute cardiostimulant and to a minor extent possibly also to the thermogenic and euphoric effects of MDMA in humans.

MeSH Terms (20)

Adrenergic alpha-1 Receptor Antagonists Adult Affect Blood Pressure Body Temperature Cross-Over Studies Double-Blind Method Doxazosin Drug Interactions Epinephrine Female Healthy Volunteers Heart Rate Humans Male N-Methyl-3,4-methylenedioxyamphetamine Norepinephrine Receptors, Adrenergic, alpha-1 Switzerland Young Adult

Connections (1)

This publication is referenced by other Labnodes entities:

Links